July Is Sarcoma Awareness Month

TON July 2016 Vol 9 No 4 - Rare Cancers
E. K. Charles, MBS

Although it is a rare disorder, approximately 14,000 new cases of sarcoma are diagnosed in the United States each year.1 Approximately 15% of cancer diagnoses among patients aged <20 years are sarcomas.

Patients should be encouraged to understand their disease. Healthcare professionals can provide pamphlets and other resources with general information about the condition, including the 2 main subtypes of sarcomas—bone and soft tissue—as well as information about the specific type of sarcoma the patient may have.

In addition, it is important to identify and educate populations that may be at higher risk for sarcomas. For example, patients with certain inherited disorders (eg, neurofibromatosis or tuberous sclerosis) may be at higher risk for soft tissue sarcomas.2 Other risk factors for soft tissue sarcomas include past treatment with radiation therapy for certain cancers, exposure to chemicals (eg, thorium dioxide), and long-term lymphedema in the arms and legs.

There are also risk factors for sarcomas of the bone; in a very small number of cases, these sarcomas may be hereditary.3 In other cases, patients with disorders such as Paget disease, or who have been exposed to radiation, may be at higher risk for bone sarcomas. Bone marrow transplantation and certain injuries have also been associated with higher risk for bone sarcomas.

Patients should also be able to recognize the signs and symptoms of sarcomas. For soft tissue sarcomas, patients may see and/or feel a painless lump under their skin; these often occur on the arm or leg.2 Other soft sarcomas may not have signs or symptoms until they grow to a certain size, such as sarcomas that start in the abdomen. In those cases, pain and trouble breathing may be signs and symptoms for patients to look for. In bone cancer, symptoms may include bone pain, swelling and tenderness near the affected area, broken bones, as well as fatigue, and unintended weight loss.4

Because other conditions may have similar symptoms, it is important that patients bring these to their healthcare provider's attention.

References

1. Sarcoma Alliance. What is sarcoma? http://sarcomaalliance.org/what-you-need-to-know/what-is-sarcoma/. Accessed June 22, 2016.
2. National Cancer Institute. Adult soft tissue sarcoma treatment. www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tissue-treatment-pdq. Updated May 23, 2016. Accessed June 22, 2016.
3. American Cancer Society. What are the risk factors for bone cancer? www.cancer.org/cancer/bonecancer/detailedguide/bone-cancer-risk-factors. Updated January 21, 2016. Accessed June 23, 2016.
4. Mayo Clinic. Bone cancer: symptoms and causes. www.mayoclinic.org/diseases-conditions/bone-cancer/symptoms-causes/dxc-20126419. Published March 17, 2015. Accessed June 23, 2016.

Related Items
Duloxetine Improves Chemotherapy-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer
Wayne Kuznar
TON - March 2017, Vol 10, No 2 published on March 7, 2017 in Rare Cancers
Defitelio (Defibrotide Sodium): FDA Approved for Patients with Hepatic Veno-Occlusive Disease
E. K. Charles, MBS
TON May 2016 Vol 9 No 3 published on May 16, 2016 in Drug Updates & News
Defitelio (Defibrotide Sodium): FDA Approved for Patients with Hepatic Veno-Occlusive Disease
E. K. Charles, MBS
TOP - May 2016, Vol 9, No 2 published on May 13, 2016 in Drug Updates & News
IDH Mutations Have Clinically Significant Implications in Patients with Primary Myelofibrosis
E. K. Charles, MBS
TOP - February 2016, Vol 9, No 1 published on February 12, 2016 in Hematologic Cancers
Early Intervention of Inflammation May Be Key in Myeloproliferative Neoplasms
E. K. Charles, MBS
TOP - February 2016, Vol 9, No 1 published on February 12, 2016 in Hematologic Cancers
Early Intervention of Inflammation May Be Key in Myeloproliferative Neoplasms
E. K. Charles, MBS
TON January 2016 Vol 9 No 1 published on January 9, 2016 in Hematologic Cancers
IDH Mutations Have Clinically Significant Implications in Patients with Primary Myelofibrosis
E. K. Charles, MBS
TON January 2016 Vol 9 No 1 published on January 9, 2016 in Hematologic Cancers
Promising Vaccine Combination Identified for Patients With Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Rare Cancers
Sorafenib Effective in Metastatic Differentiated Thyroid Cancer
Audrey Andrews
TON - August 2013 Vol 6 No 7 published on September 4, 2013 in Rare Cancers
Advances in the Treatment of Pancreatic Neuroendocrine Tumors
Caroline Helwick
TOP - December 2012 VOL 5, NO 8 published on December 20, 2012 in Rare Cancers
Last modified: July 26, 2016